]>
IRCT20140715018490N5 IRCT 2018-08-03 Vice chancellor for research, Fasa University of Medical Sciences Effectiveness of Tanacetum parthenium on inflammatory and coagulating indexes To evaluate effectiveness of Tanacetum parthenium (L) Sch. consumption on blood inflammatory and coagulating indexes 2018-04-20 anticipated 60 Complete https://irct.ir/trial/28088 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Blocked Randomized Table, Blinding description: Participants, researchers and data analyzer were blinded to the study groups. We made the placebo and therapeutic capsules like each other and labeled them by a letter -A and B. 3 Healthy individuals. Intervention 1: Treatment group: In this group; capsules with 250 mg Tanacetum parthenium (L) Sch are administrated 1 time per day for 2 weeks. Intervention 2: control group: In this group; capsules with 250 mg corn flour are administrated 1 time per day for 2 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is Because of ethical considerations
public Ebrahim Akrami
No. 34, Western Sahebolamr Ave., North Safir Blvd.
Shiraz Iran (Islamic Republic of) 7177846939 +98 71 3820 0533 akrami_e@yahoo.com Fasa University of Medical Sciences scientific Dr Mohammadreza Ataollahi
Fasa University of Medical Sciences, Ebnesina square, Fasa, Fars, Iran
Fasa Iran (Islamic Republic of) 7461686688 +98 71 5335 0994 ataollahimr@gmail.com Fasa University of Medical Sciences Iran (Islamic Republic of) age between20 and 60 negative hx of D.M negative hx of major surgery(Under 6 months) negative hx of HTN negative hx of coagulopathy like hemophilia negative hx of liver diseases Satisfaction to participate in the scheme. not use anticoaglant drugs and anti inflamatory drugs such as NSAIDs Not to have bleeding disorders in GI system 20 years 60 years Male positive hx of coagulopathy like hemophilia positive hx of HTN positive hx of major surgery(Under 6 months) positive hx of D.M liver disease such as cirihosis or hepatitis Age over 60 or under the age of 20 use anticoaglant drugs and anti inflamatory drugs such as NSAIDs Dissatisfaction to participate in the scheme To have bleeding disorders in GI system possible complications Treatment - Drugs Placebo Treatment group: In this group; capsules with 250 mg Tanacetum parthenium (L) Sch are administrated 1 time per day for 2 weeks. control group: In this group; capsules with 250 mg corn flour are administrated 1 time per day for 2 weeks. Prothrombin Time (PT). Timepoint: At the beginning of intervention, 2 weeks and 6 weeks after the beginning of intervention. Method of measurement: Venous Blood Test. Partial Thromboplastin Time (PTT). Timepoint: At the beginning of intervention, 2 weeks and 6 weeks after the beginning of intervention. Method of measurement: Venous Blood Test. IL-1β. Timepoint: At the beginning of intervention and 2weeks later. Method of measurement: Venous Blood Test. IFN-α. Timepoint: At the beginning of intervention and 2weeks later. Method of measurement: Venous Blood Test. IFN-γ. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. TNF-α. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. Monocyte chemotactic protein-1. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-6. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-8. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-10. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-12p70. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-17A. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-18. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-23. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. IL-33. Timepoint: At the beginning of intervention and 2 weeks later. Method of measurement: Venous Blood Test. Satisfaction of patients. Timepoint: 1 month after recruitment. Method of measurement: visual analog scale. Tolerance. Timepoint: 1 month after recruitment. Method of measurement: visual analog scale. Drug side effects. Timepoint: 1 month after recruitment. Method of measurement: Questionnaire. Vice chancellor for research, Fasa University of Medical Sciences Approved 2017-10-22 Ethics committee of Fasa University of Medical Sciences Fasa University of Medical Sciences, Ebnesina square, Fasa Fasa Fars Iran (Islamic Republic of)